<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800473</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01297-42</org_study_id>
    <nct_id>NCT02800473</nct_id>
  </id_info>
  <brief_title>Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection</brief_title>
  <acronym>CyPaM2</acronym>
  <official_title>Evaluation of an Innovative Medical Device Made of a Bimodal Endoscopic Imager and of a Software for Panoramic Images Building of the Bladder Inner Wall (French National Research Agency, CyPaM2 Project, ANR-11-TECS-001) (CyPaM2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the therapeutic value of: (i) simultaneous endoscopic visualization of&#xD;
      the inner bladder using white light and blue light excitations and (ii) high resolution&#xD;
      panoramic images of the bladder inner wall.&#xD;
&#xD;
      All participants will undergo fluorescence cystoscopy: the first half using first a reference&#xD;
      medical device for fluorescence cystoscopy already on the market then using the innovative&#xD;
      device specifically developped for the CyPaM2 project.&#xD;
&#xD;
      The other half will undergo fluorescence cystoscopy using first the innovative then the&#xD;
      reference medical device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An innovative medical device was developped by the CyPaM2 project's partners.This device is&#xD;
      made of a hardware and of a software part: (i) an imager (light source and sensors) for&#xD;
      simultaneous and colocalized visualisation of the bladder using white light and blue light&#xD;
      for fluorescence excitation and (ii) a mosaicing software for automatic building of&#xD;
      high-resolution panoramic images of the bladder inner wall. The medical device's qualitative&#xD;
      (human engineering, images qualitty) and quantitative (medical examination and panoramic&#xD;
      images building durations) specifications will be evaluated during the clinical trial in&#xD;
      comparison with a reference medical device already on the market. The main goals are to&#xD;
      achieve (i) better sensitivity of bladder cancers' cystocopic diagnosis and shorter medical&#xD;
      examination durations thanks to the simultaneous visualization of the bladder inner wall with&#xD;
      white and blue lights and (ii) better patients' follow up thanks to the high resolved&#xD;
      panoramic images.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2016</start_date>
  <completion_date type="Actual">October 6, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ergonomic comparaison of the two devices</measure>
    <time_frame>1 day</time_frame>
    <description>Ergonomic of the two devices will be evaluated and compared by using the scale NASA TLX (Hart SG, et al., 1998).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of performing time</measure>
    <time_frame>1 day</time_frame>
    <description>Performing time of medical examination with both devices will be evaluated and compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality assessment of image</measure>
    <time_frame>1 day</time_frame>
    <description>Image quality : sharpness and colorimetry will be assessed by the physician using a self-questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality assessment of device evaluation</measure>
    <time_frame>1 day</time_frame>
    <description>Device quality : sensitivity and accuracy will be assessed by the urologist using a self-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of recording capacity of the video sequences to perform real-time image mosaics</measure>
    <time_frame>1 day</time_frame>
    <description>Recording capacity of the video sequences to perform real-time image mosaics will be assessed by the physician using a self-questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.&#xD;
Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.&#xD;
24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Strorz (commercial)</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CyPaM2 (experimental)</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Patient with suspicion of a bladder cancer or a suspected recurrence of a bladder&#xD;
             cancer&#xD;
&#xD;
          -  Cytological and bacteriological examination of urine culture negative&#xD;
&#xD;
          -  Patient must be affiliated to a social security system&#xD;
&#xD;
          -  Ability to provide written informed consent patient's legal capacity to consent to&#xD;
             study participation and to understand and comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Bladder infection in progress and untreated&#xD;
&#xD;
          -  Hemorrhage&#xD;
&#xD;
          -  Urethral stenosis&#xD;
&#xD;
          -  Contraindication for a cystoscopy examination&#xD;
&#xD;
          -  Contraindication to administration of Hexvix (porphyria, hypersensitivity to&#xD;
             hexylaminolévulinate or excipient of Hexvix (disodium phosphate dihydrate, potassium&#xD;
             dihydrogen phosphate)&#xD;
&#xD;
          -  Pregnant or breast feeding females&#xD;
&#xD;
          -  Patients deprived of liberty or under supervision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ESCHWEGE PASCAL, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Amouroux M, Salleron J, Huin-Schohn C, Ali S, Berthaud S, Rizo P, Schneider S, Vever-Bizet C, Bourg-Heckly G, Guillemin F, Le Coupanec P, Galbrun E, Daouk J, Daul C, Blondel W, Eschwège P. Clinical evaluation of a device providing simultaneous white-light and fluorescence video streams as well as panoramic imaging during fluorescence assisted-transurethral resection of bladder cancer. J Opt Soc Am A Opt Image Sci Vis. 2019 Nov 1;36(11):C62-C68. doi: 10.1364/JOSAA.36.000C62.</citation>
    <PMID>31873695</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Hexvix</keyword>
  <keyword>Bimodal Endoscopic Imager</keyword>
  <keyword>Cystoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

